Predictors of mortality in blood stream infections caused by extended spectrum beta lactamase producing enterobacteriaceae

Chavada R*, Descallar J² and Maley M⁴

¹Department of Microbiology and Infectious Diseases, Pathology North, Gosford, NSW, Australia
²Ingham Institute of Medical Research, Liverpool, NSW, Australia
³South Western Sydney Clinical School, UNSW, Liverpool, NSW, Australia
⁴Department of Microbiology and Infectious Diseases, Liverpool, Sydney South West Pathology Service, Liverpool, NSW, Australia

Abstract

Introduction: Extended spectrum beta-lactamases (ESBL) have been increasing worldwide and are associated with increased rates of treatment failure, morbidity, healthcare costs and mortality. This study was performed to evaluate the risk factors for mortality in ESBL blood stream infections.

Methods: A descriptive retrospective observational case study was performed. Data was collected from patient medical records and laboratory information system. Phenotypic resistance testing and multiplex PCR assay was done. Standard definitions were used. Standard bivariate analysis and multivariate analysis were performed.

Results: A total of 114 patients were included in this study. 30 day mortality rate was 18.4% (21/114). Median APACHE2 score was higher in patients who died compared to those who survived [19.5 vs 16.4, p=0.002]. Urinary tract infection (61.7%) and intraabdominal (22.8 %) were the most common source of infection. On univariate analysis patients who presented with intraabdominal infection (OR 3.3[1.1-10.3, p=0.03]), received third generation cephalosporin (OR 23[2.27-233, p=0.008]) as their definitive therapy, received inappropriate definitive (OR 28[5.3-146.5, p=<0.01) and had a higher APACHE2 score >20 (p=0.008) were associated with higher mortality at 30 days. Also patients who did not receive immunosuppressive medications (OR 0.26[0.08-0.86, p=0.02]) had lower mortality at 30 days compared to those did. On multivariate analysis receipt of inappropriate antimicrobial therapy (OR 26.21[4.75-144.93, p=0.001] and APACHE2 score > 20 (OR 3.48[1.12-10.74, p=0.03] were independently associated with increased mortality.

Conclusions: Prompt institution of appropriate antimicrobial therapy (including a change from third generation cephalosporin) based on susceptibility results should be done in patients with ESBL BSI. Patients who receive inappropriate definitive antimicrobial therapy and those that present in septic shock have higher mortality with ESBL BSI.

Introduction

Extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae have become frequent worldwide, causing increased hospital morbidity and mortality [1,2]. The presence of this enzyme significantly reduces the available antimicrobial options, as ESBL genes are associated with other resistance encoding genes, which generates resistance to multiple classes of antibiotics [3,4]. The epidemiology of infections caused by these organisms has evolved and varies considerably according to geographic regions [5-7]. According to the European Antimicrobial surveillance network data, in 2012, the third generation cephalosporin resistance in Escherichia coli was 11.9% and in Klebsiella pneumoniae was 25.6%, and this had increased over the preceding surveillance period [8].

There has been a great heterogeneity of the published studies that have looked at the risk factors for blood stream infections and mortality caused by ESBL producing Enterobacteriaceae [9]. While some have looked at particular organisms or groups of organisms, others have looked at the place of acquisition of infection such as hospital vs community onset. We undertook this study to understand the local epidemiology of ESBL producing enterobacteriaceae in south western Sydney and to determine outcomes of these infections in patients presenting to our hospitals. The aim of this study was to assess the risk factors for mortality for blood stream infections (BSI) caused by ESBL producing enterobacteriaceae in our area.

Methods

Study setting and design

South Western Sydney Local Health District covers a large urban and semi-rural area with a population of approximately 1 million people. The population is generally of lower socioeconomic status, has relatively poorer health and is very ethnically diverse. Many residents have close contact with overseas visitors and travel periodically to regional countries to visit friends and relatives. The Sydney South West
Pathology Service (SSWPS) Microbiology laboratory provides services
to all of the tertiary care hospitals in the region comprising over
1600 acute hospital beds. Routine active surveillance for multi-drug
resistant (MDR) gram negative (GN) organisms is performed on the
60 plus ICU beds and on selected high risk admissions.

A descriptive retrospective observational study was performed
over a period of 3 years (January 2011- January 2014) where all cases of
bacteremia by ESBL producing enterobacteriaceae were included. The
patients were identified from the microbiology laboratory information
system and cross matched against stored organism database to ensure
almost all ESBL BSI episodes were captured. The study was approved
by the local South Western Sydney Human Research Ethics committee.

Clinical data

Electronic medical records were accessed to gather demographic
and clinical information such as age, sex, underlying disease, primary
site of infection, severity of illness as calculated by the Acute Physiology
and Chronic Health Evaluation (APACHE) 2 score, duration of hospital
stay, antimicrobial regimen, surgical procedure performed, overseas
travel, presence of indwelling catheters, nursing home admissions and
any antimicrobial therapy in the 90 days prior to onset of bacteraemia.
Comorbidities recorded included neutropenia, presentation with
septic shock, intensive care unit admission, immune suppressive
agents within 60 days prior to onset of bacteraemia, corticosteroid
and chemotherapy. The primary clinical outcome assessed was 30 day
mortality.

Definitions

‘Nosocomial infection’ was defined as an infection that occurred
48 h after admission to the hospital, an infection that occurred 48 h
after admission to the hospital in patients who had been hospitalized
in the 2 weeks prior to admission, or an infection that occurred 48 h
after admission to the hospital in patients that had been transferred
from another hospital or nursing home. All other BSI was classified to
be ‘community onset’. Immunosuppression was defined as receipt of
chemotherapy for haematological or solid organ malignancy or use of
known immunosuppressive agents for treatment of other established
conditions.

Multi-drug resistant (MDR) was defined as resistance to ≥3
different classes of antimicrobial agents.

‘Empirical therapy’ was defined as antimicrobials given before
the results of blood culture were available and ‘definitive therapy’
was defined as treatment given after the results of antibiotic susceptibility
tests had been received. The antimicrobial therapy was considered
‘appropriate’ if the treatment regimen included antibiotics active
in vitro with its dosage and route of administration in conformity
with current medical standards. Cephalosporin monotherapy was
considered inappropriate definitive therapy regardless of the minimal
inhibitory concentration (MIC). Similarly when patients continued
to received piperacillin-tazobactam or cefepime despite final
results showing the organism being resistant was also considered as
inappropriate. However the final decision about which antimicrobial
to use was not up to the investigators but to the treating physicians,
although all occasions of ESBL BSI were communicated to clinical
teams by the microbiology laboratory and this included appropriate
advice on use of antimicrobials.

Microbiological methods

Antimicrobial susceptibility testing and phenotypic confirmation
of MDR GN was performed according to Clinical Laboratory
Standards Institute (CLSI) recommendations. Vitek2 (bioMerieux,
Marcy l’Etoile, France) MIC profile was used as a screening test that
lead to phenotypic, and sometimes genotypic, confirmatory tests.
For enterobacteriaceae an MIC ≥ 2 mg/L for any one of the third
generation cephalosporins (3GC), or cefepime (FEP), or ceftazidime
(CAZ), or a gentamicin MIC ≥ 4 mg/L, or a meropenem (MEM) MIC
of ≥ 0.5 mg/L, triggers further testing. The confirmatory phenotypic
test was a combination of double disc synergy testing (DDST) and disc
approximation (DA) used in tandem on a combination of Mueller
Hinton agar (MHA) plates (CLSI). A 0.5 McFarland suspension was
used to make a lawn and commercially produced antibiotic discs were
placed at pre-set positions according to our locally validated method
for detection of ESBL, AmpC and carbapenemases [10]. Also a locally
validated commercial multiplex PCR was performed for detection of
ESBL(bla TEM , bla SHV , bla CTX-M1 , bla CTX-M9 ), AmpC(bla DHA , bla ACC , bla CMY )
and carbapenemase(bla KPC , bla OXA23 , bla IMP )[11].

Statistical analysis

Student t test was used to compare continuous variables, and
Fisher exact test was used to compare categorical variables. Binomial
univariate analysis was performed followed by multivariate backward
logistic regression analysis using SAS version 9.1(Lane Cove, NSW,
Australia).

Results

The median age of the patients in the study was 71.1 years with
61% (70/114) patients being male. Community associated ESBL BSI
was more frequently seen (64%). Comorbidities were seen in both cases
and controls including haematological and solid organ malignancy,
diabetes, chronic renal impairment (with or without dialysis), chronic
liver disease from alcohol or chronic hepatitis infection. On univariate
analysis, there was no statistical difference found in age, sex, onset or
comorbidities in the patients who died at 30 days. 30 day mortality
related to ESBL BSI was 18.4 % (21/114) (Table 1).

We found that 25/114(21.9%) were from a nursing home,
10/114(8.7%) had travelled overseas in the last 6 months and
23/114(20.1%) had recent surgery in the last 3 months. Similarly on
univariate analysis these factors did not differ between the two patient
subsets. Similarly other features that were studied included previous
hospital admission (76/114, 66.6%) for any reason (in the last 3
months), admission to intensive care unit (27/114, 23.6%), antibiotics
administered in the past 60 days (40/114, 35%) and presence of urinary
catheter for more than 6 weeks (19/114, 16.6%). There was no difference
found in terms of mortality in these variables between the subsets.
Immunosuppression was more frequent in the subset of patients who
had died as opposed to those who survived (28.5 vs. 7.8, p=0.02).

Urinary tract infections (60.5%) were most commonly seen in
this study followed by intraabdominal (22.8%), pneumonia (7%), skin
soft tissue infections (3.5%), central line associated (3.5%), and bone
and joint infections (2.6%). Escherichia coli was the most common
organism (79.8%), followed by Klebsiella pneumoniae (14%) and
Enterobacter cloacae (4%).

CTX-M1 was the most type of ESBL genotype (47.6%) followed
CTX-M9 (33.3%) (Figure 1).

Inappropriate empirical antimicrobial therapy was given in
16/21(76%) of patients who died, as opposed to 81/93(87%) of patients
who had survived. There was no statistical difference found between
the two groups. Inappropriate definitive therapy constituted cephalosporin
Table 1. Clinical characteristics of patients with ESBL BSI

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Died (n=21)</th>
<th>Survived (n=93)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>Age (years)</td>
<td>76</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Sex: Male</td>
<td>13</td>
<td>61.9</td>
<td>57</td>
</tr>
<tr>
<td>Onset</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1) Community</td>
<td>12</td>
<td>57.1</td>
<td>61</td>
</tr>
<tr>
<td>2) Hospital</td>
<td>9</td>
<td>42.9</td>
<td>32</td>
</tr>
<tr>
<td>Organisms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escherichia Coli</td>
<td>16</td>
<td>76.1</td>
<td>75</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>3</td>
<td>14.2</td>
<td>13</td>
</tr>
<tr>
<td>Others</td>
<td>2</td>
<td>9.5</td>
<td>5</td>
</tr>
<tr>
<td>Clinical diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1) Urinary tract infection</td>
<td>8</td>
<td>38</td>
<td>61</td>
</tr>
<tr>
<td>2) Intraabdominal</td>
<td>8</td>
<td>38</td>
<td>18</td>
</tr>
<tr>
<td>3) Pneumonia</td>
<td>6</td>
<td>35.2</td>
<td>11</td>
</tr>
<tr>
<td>Antibiotics Given</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1) Ciprofloxacin</td>
<td>0</td>
<td>0</td>
<td>23</td>
</tr>
<tr>
<td>2) Meropenem</td>
<td>8</td>
<td>38</td>
<td>46</td>
</tr>
<tr>
<td>3) Ceftriaxone</td>
<td>4</td>
<td>19</td>
<td>1</td>
</tr>
<tr>
<td>4) Piperacillin-tazobactam</td>
<td>7</td>
<td>33.3</td>
<td>16</td>
</tr>
<tr>
<td>5) Other-cefepime, gentamicin</td>
<td>2</td>
<td>9.5</td>
<td>7</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1) Malignancy</td>
<td>8</td>
<td>38</td>
<td>19</td>
</tr>
<tr>
<td>2) Diabetes</td>
<td>3</td>
<td>14.2</td>
<td>19</td>
</tr>
<tr>
<td>3) Renal failure</td>
<td>4</td>
<td>19.0</td>
<td>10</td>
</tr>
<tr>
<td>4) Liver disease</td>
<td>3</td>
<td>14.2</td>
<td>5</td>
</tr>
<tr>
<td>History of Travel</td>
<td>1</td>
<td>4.7</td>
<td>9</td>
</tr>
<tr>
<td>Surgery in hospital</td>
<td>3</td>
<td>14.2</td>
<td>20</td>
</tr>
<tr>
<td>ICU admission</td>
<td>3</td>
<td>14.2</td>
<td>24</td>
</tr>
<tr>
<td>Nursing home</td>
<td>6</td>
<td>28.4</td>
<td>19</td>
</tr>
<tr>
<td>Length of hospital stay</td>
<td>8</td>
<td>38</td>
<td>11</td>
</tr>
<tr>
<td>APACHE2(median) score</td>
<td>19.5</td>
<td>16.4</td>
<td></td>
</tr>
<tr>
<td>APACHE2 &gt; 20</td>
<td>11</td>
<td>52.3</td>
<td>21</td>
</tr>
<tr>
<td>Urologic procedure</td>
<td>2</td>
<td>9.5</td>
<td>16</td>
</tr>
<tr>
<td>Previous hospitalisation(&lt;3 months)</td>
<td>17</td>
<td>80.9</td>
<td>59</td>
</tr>
<tr>
<td>Indwelling catheter</td>
<td>3</td>
<td>14.2</td>
<td>16</td>
</tr>
<tr>
<td>Immunosuppressive medication</td>
<td>6</td>
<td>28.4</td>
<td>9</td>
</tr>
<tr>
<td>Inappropriate empirical treatment</td>
<td>5</td>
<td>23.8</td>
<td>12</td>
</tr>
<tr>
<td>Inappropriate definitive therapy</td>
<td>8</td>
<td>38</td>
<td>2</td>
</tr>
</tbody>
</table>

**Figure 1.** Predominant genotypes of ESBLs in patients who died.

Median APACHE 2 score was higher in patients who had died as opposed to those who had survived (19.5 vs. 16.4, p=0.002). Median hospital length of stay was 17.2 days (IQR 1-166). Antimicrobials used in order of frequency were meropenem (47.3%), ciprofloxacin (20%), piperacillin-tazobactam (20%), cefepime (6.1%), ceftriaxone (4.3%) and gentamicin (1.7%).

Source control surgery or intervention appropriate for controlling source of sepsis was performed only in 23 % of cases.

On univariate analysis patients who presented with intraabdominal infection (OR 3.3[1.1-10.3, p=0.03]), received third generation cephalosporin (OR 23[2.27-233, p=0.008]) as their definitive therapy, received inappropriate definitive (OR 28[5.3-146.5, p=0.001) and had a higher APACHE2 score >20 (p=0.008) were associated with higher mortality at 30 days. Also patients who did not receive immunosuppressive medications (OR 0.26[0.08-0.86, p=0.02]) had lower mortality at 30 days compared to those did. On multivariate analysis receipt of inappropriate antimicrobial therapy (OR 26.2[4.75-144.93, p=0.001) and APACHE2 score > 20 (OR 3.48[1.12-10.74, p=0.03) were independently associated with increased mortality (Table 2).

**Discussion**

The incidence rates of ESBL in Australia has been looked at in community based Gram negative surveillance programs where monotherapy or combination of piperacillin –tazobactam or cefepime (when tested resistant by laboratory) given to patients despite results of the organism harbouring an ESBL enzyme being communicated to the treating clinician. This was given 8/21(38%) of patients who had died.
cumulative rates of 7.1% were found for *Escherichia coli* and 4.3% for *Klebsiella pneumoniae*. These rates are significantly lower than ESBL incidence rates from countries like China, India and southern European countries (30-60%) [12,13]. We found a crude mortality rate of 18.4% which falls in the range of mortality reported from other studies which range from 8.1–43.6% [4,14,15]. In our study we found that majority of ESBL BSI were community onset (64%), which is similar to study by van Aken et al. [16] (68%) in a low prevalence setting. However other studies have found a higher percentage of nosocomial onset (80%) [17]. This difference could be related to the prevalence of ESBL in community setting and as well nosocomial factors like antimicrobial prescribing including antimicrobial stewardship, infection control practices in particular hospitals. Several other studies found that presence of more than 2 comorbidities increased the risk of mortality from ESBL BSI which was not observed in our study [17,18]. This difference could be attributed to the onset of the BSI as hospitalised patients with comorbidities in these studies as this group of patients are more likely to get such infections. Majority of ESBL BSI in our study was community onset infections. We did not find admission from Nursing home as a risk factor for mortality which was found in the study by Marchaim et al. [19].

While nosocomial onset of bacteraemia was found to be a risk factor for death in other studies we found that causes of such bacteraemias like surgery in hospital, presence of indwelling catheter, urological procedure and previous hospital admission in the 6 months were not associated with increased mortality [20]. We postulate that the difference in the epidemiology of infections and community onset of bacteraemias would be likely to contribute to this difference in our patient population. Like other studies we too found that patients with higher illness severity scores (APACHE2) had increased mortality [21,22]. Also a higher Pitt score and Charlson score have been independently associated with increased mortality in other studies [14,23].

Patients on immunosuppressants' for haematological, solid organ malignancies and organ transplants had higher mortality in our study as was found the study by Park et al. [21] and Menashe et al. [24]. This is likely to result from presentation with neutropenia with sepsis/septic shock requiring intensive care admission as was found in our study. Higher mortality was observed in our study in patients who had intraabdominal source of infection including biliary tract infections.

While inappropriate empirical therapy was found to be associated with increased mortality in several studies, we did not find this association. An important reason for this difference in finding could be attributed to the recommendation of Australian Therapeutic Guideline: Antibiotic (version 15, eTG) which suggests using intravenous gentamycin for 2 doses for all patients with suspected sepsis of unknown cause and in patients who present with overt sepsis to emergency department [25]. We found that 42% of isolates of ESBL in our study (data not shown) remained gentamycin susceptible which could explain this difference of outcome. However inappropriate definitive therapy was associated with increased mortality as was found in the study by Wang et al. [26]. One of the important reason for this finding in our study was due to continued use of third generation cephalosporin (Ceftriaxone) and beta lactam-beta lactamase inhibitor (Piperacillin-tazobactam) for definitive therapy for ESBL BSI. Continuation of these antimicrobials was the clinician’s decision despite being notified of the ESBL status of the organism. We think that it may be due to fact that these patients presented with terminal medical conditions and were entering a palliative phase of care. However it is difficult to determine on this retrospective study if these patients deteriorated within first 48-72 hours of admission due to sepsis (alone) and thus treating clinicians decided on palliative management. We did not find any differences in outcomes in patients who were treated with a carbapenem, fourth generation cephalosporin (cefeplime) and piperacillin-tazobactam. On multivariate analysis higher APACHE2 score >20 and receipt of inappropriate antimicrobial therapy was independently associated with increased mortality in patients with ESBL BSI. Tumbarello et al. [27] also found that despite adequate treatment in patients with ESBL BSI, the mortality rate remained reasonably high (18.5%) [27]. Higher APACHE2 score is also reflective that patients in our study who died presented with systemic inflammatory response syndrome (SIRS) and/or severe sepsis. Leistner et al. [28] did not find that production of ESBL by *E. Coli* isolates was associated with increased mortality in their study. Similarly another study by Wu et al. [29] did not find any difference in mortality between different strains of CTX-m producing *E Coli*. We did not find that production of CTX-M genotype was associated with increased mortality in our study.

Harriss et al. [30] found that there was no difference in outcomes of patients treated with beta lactam-beta lactamase inhibitor combination (where susceptibility was proven and ESBL organism’s MIC was within the sensitive breakpoint) compared to a carbapenem. The MIC for piperacillin-tazobactam was ≤ 8/32 for all isolates which tested “susceptible” by CLSI breakpoints. Interestingly there were no deaths observed in all patients who received a fluoroquinolone (ciprofloxacin) antibiotic as definitive therapy for ESBL BSI. Ciprofloxacin MIC by Vitek2 (BioMerieux, Marcy E’toile, France) was ≤ 0.25 µg/ml in all ESBL producing isolates who were treated with this antibiotic. While the issue of use of fluoroquinolone even when tested ‘susceptible’ has been debated due to reported failure in other studies, it is unclear as to whether the failure was due to the class of antibiotic itself [31-33]. Patients in these studies when treated with fluoroquinolones had a higher MIC 0.38 µg/ml, which still falls within the susceptible range but adequate tissue concentrations would not be achieved for treating high inoculum infections. Hence in carefully selected cases (MIC of ≤ 0.25 µg/ml) of ESBL BSI, ciprofloxacin could be used as a carbapenem sparing agent or sequentially as a de-escalation antimicrobial.

However as with fluoroquinolones there is a concern of treating infections with ESBL enterobacteriaceae with cefepime MIC of > 4 due to risk of clinical failures [34]. All patients treated with cefepime in our study had a cefepime MIC of ≤ 2 µg/ml which could explain the favourable outcomes.

We acknowledge the limitations of our study. Being a retrospective study, outcomes especially related to choice of definitive antimicrobials could not be commented upon. With stronger presence of antimicrobial stewardship in our hospitals, there is more leverage for infectious diseases physicians to discuss and rationalise antimicrobial therapy particularly for treatment of multi drug resistance organisms. We only looked at the 30 day mortality in this study and it is not possible to assess the long term outcomes of patients who had ESBL BSI. Also strategies that have shown to reduce transmission of multi drug resistance organisms like routine active surveillance in ‘high risk’ units like ICU, haematology was possible in patients who were admitted to these wards. The burden of community ESBL carriage could not be assessed as routine screening in not performed in our hospital setting.

**Table 2. Multivariate analysis.**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>OR</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Inappropriate definitive therapy</td>
<td>26.61</td>
<td>4.75</td>
<td>144.93</td>
</tr>
<tr>
<td>2) APACHE2 score &gt;20</td>
<td>3.48</td>
<td>1.12</td>
<td>10.74</td>
</tr>
</tbody>
</table>

Chavada R (2017) Predictors of mortality in blood stream infections caused by extended spectrum beta lactamase producing enterobacteriaceae

Despite the above issues, this study identifies the risk factors associated with increased mortality in ESBL BSI in Australian setting which has not been previously studied.

**Conclusion**

Prompt institution of appropriate antimicrobial therapy (including a change from third generation cephalosporin) based on susceptibility results should be done in patients with ESBL BSI. Patients who receive inappropriate definitive antimicrobial therapy and those that present in septic shock have higher mortality with ESBL BSI.

Fluroquinolones could be considered in carefully selected cases (MIC of organism ≤ 0.25) of ESBL BSI as a carbapenem sparing strategy or at de-escalation as oral therapy.

**References**